STOCK TITAN

Personalis, Inc. - PSNL STOCK NEWS

Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.

Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.

Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.

Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.

Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.

For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.

Rhea-AI Summary
Personalis, Inc. to present at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
-
Rhea-AI Summary
Personalis grants stock options and restricted stock units to new employees under its 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
none
-
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) reported a 8% decrease in total company revenue for the second quarter of 2023, with a net loss of $24.0 million. The company also announced a collaboration with National Cancer Center Hospital East and Ono Pharmaceutical Co. Ltd for biomarker analysis, renewal options under the VA MVP contract, and a second patent infringement lawsuit against Foresight Diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) to Participate in Upcoming Investor Conferences for Precision Oncology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences
-
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) to Release Q2 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags

FAQ

What is the current stock price of Personalis (PSNL)?

The current stock price of Personalis (PSNL) is $5.75 as of December 20, 2024.

What is the market cap of Personalis (PSNL)?

The market cap of Personalis (PSNL) is approximately 474.6M.

What does Personalis, Inc. specialize in?

Personalis, Inc. specializes in genome-scale diagnostics and genome-guided medicine.

What are Personalis' main products?

Their main products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test.

Who can benefit from Personalis' services?

Academic, pharmaceutical, and biotech researchers engaged in genome studies, pharmacogenomics, and cancer research can benefit from their services.

What technologies does Personalis use?

Personalis uses whole genome and exome sequencing, proprietary databases, human reference sequences, and sophisticated algorithms.

What is the mission of Personalis, Inc.?

The mission of Personalis is to pioneer genome-guided medicine by obtaining accurate genetic data and drawing reliable, medically-focused conclusions.

How does Personalis support cancer research?

Personalis provides genomic sequencing and analytics solutions that support the development of personalized cancer vaccines and next-generation cancer immunotherapies.

What recent achievements has Personalis made?

Personalis has formed key partnerships with pharmaceutical companies to advance personalized cancer treatments.

What sets Personalis apart from other genomic companies?

Personalis' comprehensive end-to-end genome sequencing and analysis solutions, coupled with their proprietary technologies, set them apart.

Why is genome sequencing important in medical research?

Genome sequencing is crucial for understanding genetic factors in diseases, enabling the development of targeted treatments and personalized medicine.

How can I stay updated on Personalis' latest news?

You can stay updated on Personalis' latest news by following their updates on StockTitan and other financial news platforms.

Personalis, Inc.

Nasdaq:PSNL

PSNL Rankings

PSNL Stock Data

474.58M
54.05M
19.3%
53.16%
4.04%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FREMONT